Phase 4 N=218 Treatment

Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3

Cataract

Bottom Line

View on ClinicalTrials.gov: NCT00719732 ↗

Enrolled (actual)

218

Serious AEs

0.5%

Results posted

Mar 2010

Primary outcome: Primary: Uncorrected Visual Acuity (UCVA) — 0.05; -0.07; 0.15; 0.20 logMAR

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: ReSTOR (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Alcon Research
Primary completion: May 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Uncorrected Visual Acuity (UCVA)	0.05; -0.07; 0.15; 0.20; -0.01	—

Summary

A prospective evaluation of the visual parameters in a series of patients bilaterally implanted with AcrySof ReSTOR +3 Intraocular Lens (IOL).

Eligibility Criteria

Inclusion Criteria

Diagnosed with cataracts

Exclusion Criteria

Pre-existing conditions that could skew the results or are contraindications for the ReSTOR intraocular lens;
<1 diopter astigmatism by keratometry readings.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00719732). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.